GlassScriptPhysician profile
Karlota May
NPI 1356046338
$702.08
in general payments reported to CMS, 2019-2025
10 companies · $534 in 2025
The $534 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $169 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $367.71 | 2024-2025 | |
| Braeburn INC. | $123.49 | 2025 | Brixadi |
| Intra-Sana Laboratories | $73.69 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Gilead Sciences, INC. | $38.14 | 2025 | |
| Axsome Therapeutics, INC. | $19.06 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.14 | 2024 | Xifaxan |
| Collegium Pharmaceutical, INC. | $16.93 | 2025 | Jornay Pm |
| Vertex Pharmaceuticals Incorporated | $16.86 | 2025 | |
| Indivior INC. | $15.12 | 2025 | Sublocade |
| Janssen Pharmaceuticals, INC | $13.94 | 2025 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karlota May listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.